Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00668031 · ClinicalTrials.gov registry record · Phase 3

Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement

A Phase 3 study, sponsored by Bayer.

Completed
Registry status
Phase 3
Development phase
359
Enrollment target

NCT00668031: Completed Phase 3 study, sponsored by Bayer.

NCT00668031 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 359 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00668031, a Phase 3 study, has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 3
Development phase
359 participants
Enrollment target

Study Summary

The purpose of this study is to assess if aprotinin (BAY A0128), given intravenously during surgery, is safe and can help reduce the amount of bleeding and the need for a blood transfusion during hip replacement surgery. Patients undergoing major surgery are at risk for significant blood loss. Because of this, there is a need for drugs that will help slow the amount of bleeding during surgery.

Interventions

  • DRUG Placebo
  • DRUG Trasylol (Aprotinin, BAYA0128)

Trial Details

FieldValue
Enrollment Target 359 participants
Start Date 2005-02
Est. Completion 2006-01
Phase Phase 3
Bayer

591 total trials

What the finished NCT00668031 record still lists

NCT00668031 is an interventional study that assigns participants to a tested intervention. The registered 359 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00668031 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00668031 about?

NCT00668031 is a clinical study titled "Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement". The purpose of this study is to assess if aprotinin (BAY A0128), given intravenously during surgery, is safe and can help reduce the amount of bleeding and the need for a blood transfusion during hip replacement surgery. Patients undergoing major surgery are at risk for significant blood loss. Becau...

What is the current status of trial NCT00668031?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 359 participants. The study started on 2005-02. Estimated completion is 2006-01.

What interventions are being tested in trial NCT00668031?

The interventions under investigation include: Placebo (DRUG), Trasylol (Aprotinin, BAYA0128) (DRUG).

Who is sponsoring clinical trial NCT00668031?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00668031's enrollment target sits among peer trials

359 1021st of 2000 higher than 979 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05118789 · 359 participants · Phase 1

    A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

  • NCT02747836 · 360 participants

    Ultrasound Analysis of Human Carpal Tunnel System

  • NCT04089046 · 360 participants · NA

    Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)

  • NCT04130503 · 360 participants · NA

    The Recovery in Stroke Using PAP Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00668031, the US trial registry maintained by the National Library of Medicine. NCT00668031 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.